Central Statistical Monitoring Copilot (RBQM)
Detects site-level data anomalies early and targets monitoring where quality risk is highest Evidence basis: A 2024 multi-study analysis covering 1111 sites reported quality metric improvement in most flagged sites after statistical monitoring actions; FDA guidance endorses centralized risk-based monitoring over blanket SDV
The Problem
“Central Statistical Monitoring Copilot for Risk-Based Quality Management in Clinical Trials”
Organizations face these key challenges:
Leadership struggles to justify RBQM investment without a defensible ROI model
Medical monitors cannot easily detect emerging safety or efficacy signals across scattered data
Site anomalies are often found late after quality issues have already propagated
Manual review of KRIs, listings, and patient profiles is slow and inconsistent
Patient-generated data from eCOA, ePRO, and wearables is difficult to integrate into central monitoring
Monitoring teams lack explainable prioritization of which sites and patients need action first
Traditional site-centric collection increases patient burden and can reduce engagement in decentralized trials
Impact When Solved
The Shift
Human Does
- •Review site data and quality metrics manually on a periodic basis
- •Coordinate monitoring priorities through spreadsheets and status updates
- •Investigate suspected anomalies and decide which sites need follow-up
- •Plan and document monitoring actions after retrospective quality review
Automation
- •No AI-driven analysis is used in the baseline workflow
- •No automated prioritization of site quality risk is performed
- •No continuous anomaly detection or signal triage is available
Human Does
- •Review prioritized site risk signals and confirm monitoring actions
- •Approve escalation, follow-up, and resource allocation decisions
- •Investigate exceptions and determine whether signals reflect true quality issues
AI Handles
- •Monitor site-level data for unusual patterns and emerging quality signals
- •Prioritize sites based on relative quality risk and action urgency
- •Generate standardized risk summaries and monitoring worklists
- •Surface early anomalies for targeted review and follow-up
Operating Intelligence
How Central Statistical Monitoring Copilot (RBQM) runs once it is live
AI surfaces what is hidden in the data.
Humans do the substantive investigation.
Closed cases sharpen future detection.
Who is in control at each step
Each column marks the operating owner for that step. AI-led actions sit above the divider, human decisions and feedback loops sit below it.
Step 1
Scan
Step 2
Detect
Step 3
Assemble Evidence
Step 4
Investigate
Step 5
Act
Step 6
Feedback
AI lead
Autonomous execution
Human lead
Approval, override, feedback
AI scans and assembles evidence autonomously. Humans do the substantive investigation. Closed cases improve future scanning.
The Loop
6 steps
Scan
Scan broad data sources continuously.
Detect
Surface anomalies, links, or emerging signals.
Assemble Evidence
Pull related records into a working case file.
Investigate
Humans interpret evidence and make case judgments.
Authority gates · 1
The system must not escalate a site, patient, or safety concern as a confirmed issue without review and judgment by a central monitor, data manager, or medical monitor. [S1][S3][S4]
Why this step is human
Investigative judgment involves ambiguity, legal considerations, and stakeholder impact that require human expertise.
Act
Carry out the human-directed next step.
Feedback
Closed investigations improve future detection.
1 operating angles mapped
Operational Depth
Technologies
Technologies commonly used in Central Statistical Monitoring Copilot (RBQM) implementations:
Key Players
Companies actively working on Central Statistical Monitoring Copilot (RBQM) solutions:
Real-World Use Cases
RBQM ROI calculator for executive decision support
A calculator lets leaders plug in their own numbers to estimate whether investing in RBQM will pay off.
Automated patient safety signal detection with contextual patient profiles
It builds a fuller picture of each trial patient and automatically looks for warning patterns so medical monitors can react sooner.
Patient-generated data capture via eCOA, ePRO, and wearables in decentralized trials
Let patients report symptoms and share health measurements from home using apps and connected devices, instead of always traveling to the trial site.